Bristol-Myers Squibb Australia Pty Ltd is discontinuing sales of the antidepressant Serzone® (nefazodone) in Australia, effective 30 April 2004, because of its current low and declining rate of use.
The company is notifying health care professionals of this decision to allow adequate time to switch those patients who are currently taking Serzone to another antidepressant and initiate new patients on alternative therapies.
Bristol-Myers Squibb is advising prescribers to consult the full prescribing information for Serzone prior to ceasing treatment with Serzone and switching patients to alternative therapy. It is also recommending that prescribers consult the Product Information for any product that they may consider as an alternative treatment.
Prescribers can obtain more information from the Bristol-Myers Squibb Medical Information Department on 1800 067 567.
Media enquiries:
Michael Moore
(03) 9213 4349 or 0407 759253
